[1]卞晓萍,刘 青,孔庆科*.应用减毒沙门菌载体递呈多糖抗原的研究进展[J].中国预防兽医学报,2019,(09):977-981.[doi:10.3969/j.issn.1008-0589.201810019]
 [J].Chinese journal of preventive veterinary medicine,2019,(09):977-981.[doi:10.3969/j.issn.1008-0589.201810019]
点击复制

应用减毒沙门菌载体递呈多糖抗原的研究进展()
分享到:

《中国预防兽医学报》[ISSN:1008-0589/CN:23-1417/S]

卷:
期数:
2019年09
页码:
977-981
栏目:
综述
出版日期:
2019-10-25

文章信息/Info

文章编号:
1008-0589(2019)09-0977-05
作者:
 

卞晓萍1刘 青2孔庆科*

 (西南大学 动物科技学院,重庆 北碚 400715)
分类号:
S855.1
DOI:
10.3969/j.issn.1008-0589.201810019
文献标志码:
B

参考文献/References:

[1] Wang Lei, Wang Xiao-huan, Bi Kuo, et al. Oral Vaccination with attenuated Salmonella typhimurium-Delivered TsPmy DNA vaccine elicits protective immunity against Trichinella spiralis in BALB/c mice [J]. PLoS Negl Trop Dis, 2016, 10(9): e0004952.
[2]Han Yue, Liu Qing, Willias S, et al. A bivalent vaccine derived from attenuated Salmonella expressing O-antigen polysaccharide provides protection against avian pathogenic Escherichia coli O1 and O2 infection [J]. Vaccine, 2018, 36(8): 1038.
[3]Han Yue, Liu Qing, Yi Jie, et al. A biologically conjugated polysaccharide vaccine delivered by attenuated Salmonella Typhimurium provides protection against challenge of avian pathogenic Escherichia coli O1 infection [J]. Pathog Dis, 2017, 75(8).doi: 10.1093/femspd/ftx102.
[4]Zheng Song-yue, Yu Bin, Zhang Ke, et al. Comparative immunological evaluation of recombinant Salmonella Typhimurium strains expressing model antigens as live oral vaccines [J]. BMC Immunol, 2012, 13(1): 54.
[5]黄小波,曹三杰,文心田,等. 减毒沙门氏菌载体及其在疫苗研究中的应用进展[J]. 中国人兽共患病学报,2008,24(5):478-480.
[6]马全英,安芳兰,刘萍,等. 减毒沙门氏菌作为口服活疫苗载体的研究进展[J]. 贵州畜牧兽医,2012,36(5):16-20.
[7]Avci F Y, Li Xiang-ming, Tsuji M, et al. A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design [J]. Nat Med, 2011, 17(12): 1602.
[8]Farka?觢 P, Fleischhackerova A, Bystrick?伥 S. Glycoconjugate vaccines [J]. Chem Listy, 2014, 108(2): 120.
[9]房晓文,李扬陇,黄昌炳,等. 仔猪副伤寒弱毒菌苗的研究[J]. 畜牧兽医学报,1981,12(2):99-106.
[10]朱春红,孙晓庆,何素芬,等. 基于Red同源重组和高效自杀性载体系统构建肠炎沙门氏菌突变株方法的比较[J]. 中国预防兽医学报,2009,31(2):81-84.
[11]Viala J P, Méresse S, Pocachard B, et al. Sensing and adaptation to low pH mediated by inducible amino acid decarboxylases in Salmonella [J]. Plos One, 2011, 6(7): e22397.
[12]Dharmasena M N, Feuille C M, Starke C E C, et al. Development of an acid-resistant Salmonella Typhi Ty21a attenuated vector for improved oral vaccine delivery [J]. PLoS One, 2016, 11(9): e0163511.
[13]Wu Yun, Chakravarty S, Li Ming-lin, et al. Development of a live attenuated bivalent oral vaccine against Shigellasonnei Shigellosis and Typhoid Fever [J]. J Infect Dis, 2017, 215(2):259-268.
[14]Zhao Xin-xin, Dai Qin-long, Zhu De-kang, et al. Recombinant attenuated Salmonella Typhimurium with heterologous expression of the Salmonella Choleraesuis O-polysaccharide: high immunogenicity and protection [J]. Sci Rep, 2017, 7(1): 7127.
[15]Li Pei, Liu Qing, Luo Hong-yan, et al. Bi-valent polysaccharides of Vi capsular and O9 O-antigen in attenuated Salmonella Typhimurium induce strong immune responses against these two antigens [J]. NPJ Vaccines, 2018, 3: 1.
[16]Dharmasena M N, Hanisch B W, Wai T T, et al. Stable expression of Shigella sonnei form I O-polysaccharide genes recombineered into the chromosome of live Salmonella oral vaccine vector Ty21a [J]. IJMM, 2013, 303(3): 105-113.
[17]Xu De-qi, Cisar J O, Osorio M, et al. Core-linked LPS expression of Shigella dysenteriae serotype 1 O-antigen in live Salmonella Typhi vaccine vector Ty21a: preclinical evidence of immunogenicity and protection [J]. Vaccine, 2007, 25(33):6167-6175.
[18]Dharmasena M N, Osorio M, Takeda K, et al. Stable chromosomal expression of Shigella flexneri 2a and 3a O-antigens in the live Salmonella oral vaccine vector Ty21a [J]. Clin Vaccine Immunol, 2017, 24(12): e00181-17.
[19]Moustafa D A, Scarff J M, Garcia P P, et al. Recombinant Salmonella expressing Burkholderia mallei LPS O antigen provides protection in a murine model of melioidosis and glanders [J]. PLoS One, 2015, 10(7): e0132032.
[20]Bridge D R, Whitmire J M, Makobongo M O, et al. Heterologous Pseudomonas aeruginosa O-antigen delivery using a Salmonella enterica serovar Typhimurium wecA mutant strain [J]. Int J Med Microbiol, 2016, 306(7): 529-540.
[21]Digiandomenico A, Rao J, Goldberg J B. Oral Vaccination of BALB/c Mice with Salmonella enterica Serovar Typhimurium expressing Pseudomonas aeruginosa O antigen promotes increased survival in an acute fatal pneumonia model [J]. Infect Immun, 2004, 72(12): 7012-7021.
[22]Kun Xiong, Zhu Chun-yue, Chen Zhi-jin, et al. Vi capsular polysaccharide produced by recombinant Salmonella enterica Serovar Paratyphi a confers immunoprotection against infection by Salmonella enterica Serovar Typhi [J]. Front Cell Infect Microbiol, 2017: 7: 135.
[23]Wang Jin-yuan, Noriega F R, Galen J E, et al. Constitutive expression of the vi polysaccharide capsular antigen in attenuated salmonella enterica serovartyphi oral vaccine strain CVD 909[J]. Infect Immun, 2000, 68(8): 4647.
[24]张春杰,陈松彪,程相朝,等. 鼠伤寒沙门菌SL1344株侵袭性蛋白B缺失株asd平衡致死系统的构建及特性的研究[J]. 中国免疫学杂志,2016,(2):210-213.
[25]黄维. 染色体-质粒平衡致死系统的构建及应用[J]. 生物技术通讯,2002,13(5):378-382.
[26]谢贵林,赵志强. b型流感嗜血杆菌结合疫苗[J]. 国际生物制品学杂志,2014,37(3):105-109.
[27]梁康,赵新新,易洁,等. 应用遗传改造的沙门菌介导肿瘤治疗的研究进展[J]. 生物工程学报,2016,32(5):565-576.
(本文编辑:李 爽)

更新日期/Last Update: 2019-10-29